Table 7.

%PTA and %CFR for All isolates, Colistin-susceptible isolates subgroup and Colistin-resistant isolates subgroup.

	All Isolates			Colistin-Susceptible Isolates							Colistin-Resistant Isolates
			%CFR	Colistin-Susceptible K. pneumoniae Subgroup			Colistin-Susceptible E. coli Subgroup			%CFR for all Sus-Ceptible Isolates	Colistin-Resistant K. pneumoniae Subgroup			Colistin-Resistant E. coli Subgroup			%CFR for all Resistant Isolates
	%PTA			%PTA		%CFR	%PTA		%CFR		%PTA		%CFR	%PTA		%CFR
MIC (mcg/mL)	MIC50	MIC90		MIC50	MIC90		MIC50	MIC90			MIC50	MIC90		MIC50	MIC90
	1	16		0.5	2		0.5	0.5			16	32		8	32
CrCl ≥80 mL/min
150 mg q12 h (EMA, FDA)	82.47	7.08	70.68	92.66	64.41	85.41	92.66	92.66	90.40	86.34	7.08	1.51	12.45	19.48	1.51	20.33	13.40
180 mg q12 h (Nation et al.)	85.55	8.99	73.14	97.91	69.2	87.87	97.91	97.91	92.25	88.69	8.99	2.2	15.08	24.09	2.2	24.18	16.18
150 mg q8 h (Siriraj)	90.07	19.48	78.56	98.68	79.7	92.02	98.68	98.68	95.06	92.58	19.48	7.02	25.45	39.3	7.02	35.99	26.71
CrCl 51 to 79 mL/min
114 mg q12 h (FDA)	87.96	9.8	74.90	95.95	71.98	89.91	95.95	95.95	94.07	90.69	9.8	2.36	15.94	25.05	2.36	25.26	17.06
150 mg q12 h (Siriraj, EMA, Nation et al)	91.66	13.73	77.96	97.26	78.32	92.65	97.26	97.26	95.82	93.24	13.73	3.8	20.53	32.72	3.8	31.22	21.81
CrCl 30 to 50 mL/min
150 mg q24 h (FDA)	90.53	3.58	74.65	97.55	71.1	91..27	97.55	97.55	95.58	92.07	3.58	0.39	10.05	15.59	0.39	18.84	11.10
100 mg q12 h (Siriraj)	95.34	18.09	81.26	98.89	85.65	95.74	98.89	98.89	97.90	96.14	18.09	5.58	25	38.9	5.58	36.58	26.39
110 mg q12 h (Nation et al.)	96.29	20.03	82.17	99.03	87.43	96.35	99.03	99.03	98.19	96.70	20.03	6.41	27.05	42.66	6.41	39.01	28.48
125 mg q12 h (EMA)	97.71	23.65	83.51	99.15	89.8	97.18	99.15	99.15	98.52	97.43	23.65	8.09	30.41	46.87	8.09	42.66	31.87
CrCl 11 to 29 mL/min
60 mg q24 h (FDA)	83.41	3.57	70.63	96.33	56.2	86.26	96.33	96.33	97.91	87.56	3.57	0.42	8.11	13.11	0.42	14.41	8.87
150 mg q24 h (EMA, Siriraj)	97.92	11.16	81.45	99.67	89.35	97.44	99.67	99.67	99.61	97.73	11.16	2.02	20.20	33.24	2.02	33.27	21.77
180 mg q24 h (Nation et al.)	97.93	11.23	81.45	99.63	89.32	97.41	99.63	99.63	99.93	97.70	11.23	1.94	20.29	33.41	1.94	33.4	21.87
CrCl≤10 mL/min
60 mg q24 h (FDA)	94.94	11.81	78.82	99.5	77.09	94.47	99.5	99.5	99.99	95.11	11.81	2.61	17.88	28.19	2.61	27.44	19.03
120 mg q24 h (EMA)	99.34	21.74	84.70	99.94	94.92	98.91	99.94	99.94	99.99	99.04	21.74	5.98	29.99	48.29	5.98	43.72	31.63
150 mg q24 h (Nation et al.)	99.76	28.36	86.51	99.98	97.4	99.47	99.98	99.98	100	99.54	28.36	8.69	36.24	57.76	8.69	50.55	37.96

MICs = minimum inhibitory concentrations (mcg/mL), PTA = Probability of target attainment, CFR = Cumulative fraction of response, CrCl = Creatinine clearance (ml/min), EMA = European Medicine Agency, FDA = US-Food and Drug Administration. The alternative data of Table 7 were shown in Supplementary Materials Table S6.